Showing results (241-250 of 251) with videos related to

Sort By:
Pageof 26
International Journal of Cancer|June 6, 2025
Combination therapy with levofloxacin and the probiotic Clostridium butyricum MIYAIRI 588 enhances immune checkpoint inhibitor efficacyKohei Tajima, Masahiro Hosonuma, Eiji Funayama, et al.
Anticancer Research|December 30, 2023
Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse ModelTsubasa Goshima, Katsuaki Ieguchi, Nobuyuki Onishi, et al.
Cancer Science|January 23, 2024
Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefitMasahiro Hosonuma, Yuya Hirasawa, Atsuo Kuramasu, et al.
Frontiers in Immunology|May 19, 2023
Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitorKazuyuki Hamada, Junya Isobe, Kouya Hattori, et al.
Discover Oncology|March 18, 2025
Ki-67 expression in anti-programmed cell death protein-1 antibody-bound CD8+ T cells as a predictor of clinical benefitToshiaki Tsurui, Masahiro Hosonuma, Aya Sasaki, et al.
Scientific Reports|October 8, 2024
MHC class I polypeptide-related sequence B shedding modulates pancreatic tumor immunity via the activation of NKG2DLow T cellsHitoshi Toyoda, Atsuo Kuramasu, Masahiro Hosonuma, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|December 25, 2024
Oral administration of Bifidobacterium longum and Bifidobacterium infantis ameliorates cefcapene pivoxil-induced attenuation of anti-programmed cell death protein-1 antibody action in miceEiji Funayama, Masahiro Hosonuma, Kohei Tajima, et al.
Scientific Reports|May 17, 2024
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibodyMasakazu Murayama, Masahiro Hosonuma, Atsuo Kuramasu, et al.
Frontiers in Immunology|October 4, 2023
Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitorsRyotaro Ohkuma, Sakiko Miura, Satoshi Muto, et al.
Cancer Immunology, Immunotherapy : CII|August 19, 2025
Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunityYoichiro Narikawa, Atsuo Kuramasu, Masahiro Hosonuma, et al.
Pageof 26